SJ733

Kentucky/Eisai

Product vision
  • Part of a single-exposure radical cure

MoA
  • PfATP4 inhibitor
Key features
  • Novel chemotype for clinically-validated pathway; First validated new molecular target in 20 years: very rapid killing of parasites 

  • Good physical properties and developability

  • Potential for transmission-blocking activity in a Standard Membrane Feeding Assay

Challenges
  • Cost of goods: chiral molecule

  • Human PK: exposure levels different than predicted

Status
  • First-in-human study recruiting

Next milestone
  • Complete first in human studies with extension cohorts to test use of “pharmacoenhancer”

Previously
  • Name (+)-SJ000557733; Discovery Partnership with St Jude Children’s Research Hospital and Rutgers University

MMV Project Director
  • Dr Andrew Slade